Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$175.69M$175.69M+14.2% vs Q3 2023 Net Income$38.50M$38.50MN/M vs Q3 2023 EPS Diluted$0.69$0.69N/M vs Q3 2023 Operating Income$40,845,000+401.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$53,320,000+49.3% Margins · derivedOperating margin23.2%+18.0 pt vs Q3 2023
Net margin21.9%+32.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end